Last updated: October 13, 2021
Sponsor: Sunshine Lake Pharma Co., Ltd.
Overall Status: Active - Not Recruiting
Phase
2/3
Condition
Depression
Treatment
N/AClinical Study ID
NCT04984512
HEC113995-P-5
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- 1.a Man or a woman with major depressive disorder(MDD) as the primary diagnosisaccording to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (classification code 296.22、296.23、296.32、296.33)
- 2.Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score of 26 or greaterat Screening and Baseline Visits.
- 3.Has a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greaterat Screening and Baseline Visits.
Exclusion
Exclusion Criteria:
- 1.has major depressive disorder with psychotic features according to the DSM-5.
- 2.Current or history of: bipolar disorder、schizophrenia、anixety disorder、insomnia、anysubstance abuse or dependence and other psychiatry disorder as defined in the DSM-5.
- 3.Current or history of a clinically significant neurological disorder (includingepilepsy、Alzheimer disease, Parkinson disease, multiple sclerosis, Huntingtondisease).
- has Serious body disease such as neurological disorders、cardiacvasculardisorders、hepatic disorders、 renal disorders, blood system disorders and endocrinedisorders.
- Current or history of cancer( except basal cell of the skin and preinvasivecarcinoma of cervix uteri).
- Current or history of angle-closure glaucoma.
- has made a suicide behavior in the previous 1 year ,or has a score greater than orequal to 4 on item 10 (suicidal thoughts) of MADRS .
- 8.has taken fluoxetine within 4 weeks prior to initial dosing.
- has taken other antidepressive medications or antipsychotic medications within 2weeks prior to initial dosing.
- 10.has psychotherap at Screening and/or Baseline Visits.
- 11.has had physiotherapy within 3 months prior to initial dosing.
- 12.Has an alanine aminotransferase, aspartate aminotransferase or total bilirubinlevel greater than 1.5 times the upper limits of normal.
- 13.Has an alanine aminotransferase, aspartate aminotransferase level greater than 2times the upper limits of normal;or total bilirubin, direct bilirubin,creatinine levelgreater than 1.5 times the upper limits of normal;or a thyroid stimulating hormonevalue outside the normal range.
- 14.Has an abnormal electrocardiogram confirmed as clinically significant by theinvestigator.
- 15.Has a history of severe allergies.
Study Design
Total Participants: 600
Study Start date:
November 01, 2021
Estimated Completion Date:
May 31, 2024